Stanford has developed a molecule that can be attached to a standard drug used to treat antibiotic-resistant infections. A report from RxNet. 

Antibiotic resistance is one of the major health concerns facing scientists in recent years. MRSA is the most well-known antibiotic-resistant infection; it is the cause of more than 50% of hospital-related infections in Asia and the Americas and leads to the most antibiotic-resistant infection-related deaths.

Lynette Cegelski, associate professor of chemistry in the School of Humanities and Sciences at Stanford University and advisor on the project reasoned, “It’s a global health problem, and we need new treatment strategies, because of the increasing emergence of bacteria that are resistant to antibiotics and the limited number of antibiotics in our pipeline.”

The number of FDA-approved antibiotics has dramatically decreased in the last 30 years, but as much as 90%, and the current treatment plan for a MRSA infection has been in place since 1958.

Cegelski’s team at Stanford are trying to overcome the problem attaching a molecule to an antibiotic considered the last resort in treating antibiotic resistance infections. You can read more about this innovative approach on RxNet, which covers the drug discovery and development pipeline.